Literature DB >> 2873544

Imaging of metastatic medullary carcinoma of the thyroid with 131I-meta-iodobenzyl guanidine.

G J Poston, A M Thomas, D W Macdonald, D Karvounaris, B L Henderson, P George, J A Lynn, J P Lavender.   

Abstract

The uptake of 131I-MIBG by medullary carcinoma of the thyroid was studied in six patients after total thyroidectomy in whom persistent raised plasma calcitonin levels were indicative of residual disease. The only patient in whom any activity in a possible metastasis was seen had by far the highest level of circulating calcitonin of the group and in contrast one patient with a presumptive metastatic deposit showed no uptake of MIBG into it. In conclusion the uptake of 131I-MIBG by medullary carcinoma of the thyroid is unreliable and unpredictable.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873544     DOI: 10.1097/00006231-198604000-00003

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  3 in total

1.  (131I)meta-iodobenzylguanidine scintigraphy and selective venous catheterization after thyroidectomy for medullary thyroid carcinoma.

Authors:  G Lupoli; G Lombardi; N Panza; B Biondi; G Pacilio; S Lastoria; M Salvatore
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

2.  The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience.

Authors:  L Troncone; V Rufini; P Montemaggi; F M Danza; A Lasorella; R Mastrangelo
Journal:  Eur J Nucl Med       Date:  1990

3.  Detection of cervical metastases of thyroid medullary carcinoma by MoAb anti-CEA scintigraphy and immunohistochemistry.

Authors:  S Parkkila; A Ahonen; P Torniainen; J Heikkilä; P Salmela
Journal:  Eur J Nucl Med       Date:  1995-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.